Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.12
Dollar change
-0.11
Percentage change
-3.41
%
Index- P/E- EPS (ttm)-0.35 Insider Own4.88% Shs Outstand31.15M Perf Week-15.45%
Market Cap99.53M Forward P/E- EPS next Y-0.45 Insider Trans2.64% Shs Float30.34M Perf Month-11.11%
Income-10.74M PEG- EPS next Q-0.10 Inst Own13.87% Short Float1.97% Perf Quarter-20.81%
Sales0.21M P/S473.94 EPS this Y-37.50% Inst Trans6.50% Short Ratio3.86 Perf Half Y-4.00%
Book/sh0.77 P/B4.03 EPS next Y-2.27% ROA-40.03% Short Interest0.60M Perf Year-31.28%
Cash/sh0.75 P/C4.18 EPS next 5Y- ROE-41.01% 52W Range2.75 - 6.45 Perf YTD-19.59%
Dividend Est.- P/FCF- EPS past 5Y16.79% ROI-43.48% 52W High-51.63% Beta0.85
Dividend TTM- Quick Ratio15.19 Sales past 5Y-55.51% Gross Margin77.14% 52W Low13.45% ATR (14)0.28
Dividend Ex-Date- Current Ratio15.19 EPS Y/Y TTM12.81% Oper. Margin-5744.76% RSI (14)38.92 Volatility8.86% 8.24%
Employees5 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin-5116.19% Recom1.00 Target Price12.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-37.82% Payout- Rel Volume0.80 Prev Close3.23
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume154.68K Price3.12
SMA20-8.68% SMA50-21.13% SMA200-13.20% Trades Volume123,504 Change-3.41%
Date Action Analyst Rating Change Price Target Change
Dec-23-22Initiated Chardan Capital Markets Buy $8
Apr-12-21Initiated H.C. Wainwright Buy $11
Mar-14-24 08:45AM
Mar-11-24 08:00AM
Feb-12-24 07:30AM
Jan-29-24 08:50AM
Jan-23-24 07:55AM
08:47AM Loading…
Jan-16-24 08:47AM
Jan-10-24 09:00AM
Dec-14-23 07:15AM
Dec-11-23 12:26PM
Dec-06-23 06:00PM
04:05PM
Nov-27-23 08:30AM
Oct-31-23 08:30AM
Oct-30-23 07:38AM
Oct-23-23 08:30AM
05:36AM Loading…
Oct-20-23 05:36AM
Oct-13-23 09:55AM
08:30AM
Oct-12-23 11:08AM
Oct-03-23 08:30AM
Sep-21-23 12:00PM
Sep-19-23 08:30AM
Sep-11-23 10:11PM
Aug-31-23 08:30AM
Aug-28-23 08:30AM
Aug-14-23 08:30AM
Aug-10-23 09:30AM
Aug-07-23 08:30AM
Jul-27-23 08:30AM
Jul-24-23 10:44AM
12:05PM Loading…
Jul-21-23 12:05PM
Jul-14-23 10:56AM
Jul-13-23 07:08AM
Jul-11-23 10:24AM
08:30AM
Jul-07-23 10:42AM
Jun-22-23 12:00PM
May-22-23 08:30AM
Apr-25-23 09:40AM
Apr-18-23 11:43AM
Apr-17-23 03:27PM
01:35PM
Apr-14-23 08:50AM
Apr-03-23 08:47AM
Mar-27-23 08:30AM
Mar-13-23 08:30AM
Mar-02-23 08:30AM
Feb-27-23 08:30AM
Feb-21-23 08:30AM
Jan-24-23 07:59AM
Dec-28-22 10:39AM
06:11AM
Dec-19-22 08:30AM
Dec-08-22 08:30AM
Nov-08-22 08:30AM
Oct-31-22 08:30AM
Oct-26-22 08:30AM
Oct-25-22 07:51AM
Oct-10-22 08:30AM
Sep-12-22 08:30AM
Aug-31-22 08:30AM
Aug-15-22 08:30AM
Jul-21-22 08:30AM
Jun-21-22 08:30AM
May-18-22 06:16AM
May-05-22 08:30AM
May-02-22 09:40AM
Apr-28-22 08:30AM
Apr-06-22 08:30AM
Mar-30-22 12:45PM
Mar-17-22 08:30AM
Jan-25-22 08:30AM
Jan-24-22 08:30AM
Dec-16-21 08:30AM
Dec-09-21 04:38AM
Dec-08-21 07:47AM
Dec-07-21 08:30AM
Oct-26-21 08:35AM
Oct-06-21 08:30AM
Oct-01-21 08:30AM
Sep-27-21 02:01PM
Sep-14-21 08:31AM
Sep-08-21 08:30AM
Sep-07-21 08:30AM
Aug-31-21 11:08AM
Aug-30-21 08:30AM
Aug-25-21 03:14PM
08:30AM
Aug-23-21 08:30AM
Aug-18-21 08:30AM
Jun-12-21 03:12AM
May-26-21 08:30AM
May-20-21 08:30AM
May-07-21 08:30AM
Apr-21-21 02:54PM
Apr-19-21 12:58PM
08:30AM
Apr-14-21 09:13PM
Apr-05-21 08:30AM
Mar-22-21 10:00PM
Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KUMAR AMITChief Executive OfficerMar 15 '24Buy3.2230,00096,600491,925Mar 15 10:49 AM
Baskies Arnold MDirectorMar 15 '24Buy3.6310,00036,300110,000Mar 15 02:15 PM
Titterton Lewis H jrDirectorOct 10 '23Option Exercise2.5816,00041,200823,028Oct 11 10:35 AM
KUMAR AMITChief Executive OfficerJul 31 '23Sale3.5711,80042,126461,925Jul 31 06:34 PM
KUMAR AMITChief Executive OfficerJul 28 '23Option Exercise2.5840,000103,000502,100Jul 31 06:34 PM
Titterton Lewis H jrDirectorJul 27 '23Option Exercise2.58120,000309,000894,070Jul 31 06:36 PM
Catelani MichaelPresident, COO & CFOJul 20 '23Buy3.645,50020,02026,655Jul 21 10:06 AM